Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Red Rise (lovastatin + berberine) is a preclinical-stage oral combination product being developed by Mogon Pharmaceuticals, a Swiss pharmaceutical company specializing in drug delivery systems. The formulation combines monacolin K (also referred to as monacoline or mevacolin, and chemically identical to lovastatin), a statin-class HMG-CoA reductase inhibitor derived from red yeast rice, with berberine, a plant-derived alkaloid with antidiabetic and lipid-modulating properties. The product is designed as an improved or modified oral-release tablet intended for cholesterol lowering (hypercholesterolemia), leveraging a synergistic effect between the HMG-CoA reductase inhibition of the statin component and the metabolic regulatory mechanisms of berberine, which include AMPK activation and PCSK9 downregulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lovastatin + berberine.